Clinical trial · Interventional
Study of XL999 in Adults With Solid Tumors
A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors
NCT00104117CI-TRIAL-00003171completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| XL999 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of XL999 administered as a single 4-hour intravenous (IV) infusion in subjects with solid tumors
- timeFrame
- Inclusion until 30 days post last treatment
Secondary outcomes (2)
- measure
- To evaluate plasma pharmacokinetics (PK) and estimate renal elimination of XL999 administered as a single 4-hour IV infusion in subjects with solid tumors
- timeFrame
- Various timepoints from pre-dosing until 48 hours post dose.
- measure
- To evaluate the PK of XL999 administered at a fixed weekly dose of 200 mg.
- timeFrame
- At various timepoints from pre-dosing until 48 hours post dosing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced solid tumor * Cancer that has progressed on currently available therapies * Life expectancy of \>3 months * Adequate bone marrow, liver, and kidney function * Willing to use accepted method of contraception during the course of the study * Negative pregnancy test (females) * Written informed consent Exclusion Criteria: * Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy) * Radiotherapy within 4 weeks of the start of treatment * Subjects with known brain metastasis * Uncontrolled medical disorder such as infection or cardiovascular disease * Subjects known to be HIV positive * Pregnant or breastfeeding women
References
Publications (0)
Data not yet available
No reference posted for this study.